Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells

Cancer Immunology, Immunotherapy

Volumn 58, Issue 6, 2009, Pages 915-930

  Karagiannis, Panagiotis ^a,d   Singer, Josef ^d   Hunt, James ^b   Gan, Samuel K E ^b   Rudman, Sarah M ^b   Mechtcheriakova, Diana ^d   Knittelfelder, Regina ^d   Daniels, Tracy R ^c   Hobson, Philip S ^b   Beavil, Andrew J ^b   Spicer, James ^b   Nestle, Frank O ^a   Penichet, Manuel L ^c   Gould, Hannah J ^b   Jensen Jarolim, Erika ^d   Karagiannis, Sophia N ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

HER2 neu; IgE; Mast cells; Monocytes; Trastuzumab; Tumour immunity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN E ANTIBODY; TRASTUZUMAB; TRASTUZUMAB IMMUNOGLOBULIN E ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ACTIVATION; CELL ASSAY; CELL FUNCTION; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIGAND BINDING; MAST CELL; MAST CELL DEGRANULATION; MONOCYTE; NUCLEOTIDE SEQUENCE; PHAGOCYTOSIS; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL SURVIVAL; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN E; MONOCYTES; PHAGOCYTOSIS; PROTEIN ENGINEERING; RECEPTOR, ERBB-2; RECEPTORS, IGE;

EID: 63949083569     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0607-1     Document Type: Article

References (57)

1. I Rubin Y Yarden 2001 The basic biology of HER2 Ann Oncol 12 Suppl 1 S3 S8
2. S Kaptain LK Tan B Chen 2001 Her-2/neu and breast cancer Diagn Mol Pathol 10 139 152
3. Y Yarden 2001 Biology of HER2 and its importance in breast cancer Oncology 61 Suppl 2 1 13
4. R Landgraf 2007 HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks Breast Cancer Res 9 202
5. GN Hortobagyi 2005 Trastuzumab in the treatment of breast cancer N Engl J Med 353 1734 1736
6. P Carter L Presta CM Gorman JB Ridgway D Henner WL Wong AM Rowland C Kotts ME Carver HM Shepard 1992 Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 4285 4289
7. AM Gonzalez-Angulo F Morales-Vasquez GN Hortobagyi 2007 Overview of resistance to systemic therapy in patients with breast cancer Adv Exp Med Biol 608 1 22
8. CA Hudis 2007 Trastuzumab-mechanism of action and use in clinical practice N Engl J Med 357 39 51
9. ST Lee-Hoeflich L Crocker E Yao T Pham X Munroe KP Hoeflich MX Sliwkowski HM Stern 2008 A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy Cancer Res 68 5878 5887
10. Y Izumi L Xu E di Tomaso D Fukumura RK Jain 2002 Tumour biology: herceptin acts as an anti-angiogenic cocktail Nature 416 279 280
11. M Barok J Isola Z Palyi-Krekk P Nagy I Juhasz G Vereb P Kauraniemi A Kapanen M Tanner J Szollosi 2007 Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance Mol Cancer Ther 6 2065 2072
12. GA Lazar W Dang S Karki O Vafa JS Peng L Hyun C Chan HS Chung A Eivazi SC Yoder 2006 Engineered antibody Fc variants with enhanced effector function Proc Natl Acad Sci U S A 103 4005 4010
13. R Gennari S Menard F Fagnoni L Ponchio M Scelsi E Tagliabue F Castiglioni L Villani C Magalotti N Gibelli 2004 Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 Clin Cancer Res 10 5650 5655
14. MX Sliwkowski JA Lofgren GD Lewis TE Hotaling BM Fendly JA Fox 1999 Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin Oncol 26 60 70
15. G Riethmuller JP Johnson 1992 Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers Curr Opin Immunol 4 647 655
16. HJ Gould P Takhar HE Harries SR Durham CJ Corrigan 2006 Germinal-centre reactions in allergic inflammation Trends Immunol 27 446 452
17. HJ Gould BJ Sutton AJ Beavil RL Beavil N McCloskey HA Coker D Fear L Smurthwaite 2003 The biology of IGE and the basis of allergic disease Annu Rev Immunol 21 579 628
18. RA Clynes TL Towers LG Presta JV Ravetch 2000 Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 443 446
19. RS Geha B Helm H Gould 1985 Inhibition of the Prausnitz-Kustner reaction by an immunoglobulin epsilon-chain fragment synthesised in E. coli Nature 315 577 578
20. C Gonzalez-Espinosa S Odom A Olivera JP Hobson ME Martinez A Oliveira-Dos-Santos L Barra S Spiegel JM Penninger J Rivera 2003 Preferential signalling and induction of allergy-promoting lymphokines upon weak stimulation of the high affinity IgE receptor on mast cells J Exp Med 197 1453 1465
21. AB Riemer E Untersmayr R Knittelfelder A Duschl H Pehamberger CC Zielinski O Scheiner E Jensen-Jarolim 2007 Active induction of tumor-specific IgE antibodies by oral mimotope vaccination Cancer Res 67 3406 3411
22. E Jensen-Jarolim G Achatz MC Turner S Karagiannis F Legrand M Capron ML Penichet JA Rodriguez AG Siccardi L Vangelista 2008 AllergoOncology: the role of IgE-mediated allergy in cancer Allergy 63 1255 1266
23. E Reali JW Greiner A Corti HJ Gould F Bottazzoli G Paganelli J Schlom AG Siccardi 2001 IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines Cancer Res 61 5517 5522
24. MC Turner Y Chen D Krewski P Ghadirian 2006 An overview of the association between allergy and cancer Int J Cancer 118 3124 3132
25. MC Turner Y Chen D Krewski P Ghadirian MJ Thun EE Calle 2005 Cancer mortality among US men and women with asthma and hay fever Am J Epidemiol 162 212 221
26. E Nagy I Berczi AH Sehon 1991 Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus Cancer Immunol Immunother 34 63 69
27. MH Kershaw PK Darcy JA Trapani D MacGregor MJ Smyth 1998 Tumor-specific IgE-mediated inhibition of human colourectal carcinoma xenograft growth Oncol Res 10 133 142
28. AB Riemer M Klinger S Wagner A Bernhaus L Mazzucchelli H Pehamberger O Scheiner CC Zielinski E Jensen-Jarolim 2004 Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu J Immunol 173 394 401
29. HJ Gould GA Mackay SN Karagiannis CM O'Toole PJ Marsh BE Daniel LR Coney VR Zurawski Jr M Joseph M Capron 1999 Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma Eur J Immunol 29 3527 3537
30. SN Karagiannis MG Bracher RL Beavil AJ Beavil J Hunt N McCloskey RG Thompson N East F Burke BJ Sutton 2008 Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells Cancer Immunol Immunother 57 247 263
31. SN Karagiannis MG Bracher J Hunt N McCloskey RL Beavil AJ Beavil DJ Fear RG Thompson N East F Burke 2007 IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells J Immunol 179 2832 2843
32. SN Karagiannis Q Wang N East F Burke S Riffard MG Bracher RG Thompson SR Durham LB Schwartz FR Balkwill 2003 Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells Eur J Immunol 33 1030 1040
33. RM Luiten GJ Fleuren SO Warnaar SV Litvinov 1996 Target-specific activation of mast cells by immunoglobulin E reactive with a renal cell carcinoma-associated antigen Lab Invest 74 467 475
34. RM Luiten SO Warnaar J Schuurman SG Pasmans S Latour M Daeron GJ Fleuren SV Litvinov 1997 Chimeric immunoglobulin E reactive with tumor-associated antigen activates human Fc epsilon RI bearing cells Hum Antibodies 8 169 180
35. MW Teng MH Kershaw JT Jackson MJ Smyth PK Darcy 2006 Adoptive transfer of chimeric FcepsilonRI gene-modified human T cells for cancer immunotherapy Hum Gene Ther 17 1134 1143
36. JP Cook AJ Henry JM McDonnell RJ Owens BJ Sutton HJ Gould 1997 Identification of contact residues in the IgE binding site of human FcepsilonRIalpha Biochemistry 36 15579 15588
37. MS Neuberger GT Williams EB Mitchell SS Jouhal JG Flanagan TH Rabbitts 1985 A hapten-specific chimaeric IgE antibody with human physiological effector function Nature 314 268 270
38. JS Dela Cruz SY Lau EM Ramirez C De Giovanni G Forni SL Morrison ML Penichet 2003 Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice Vaccine 21 1317 1326
39. HS Cho K Mason KX Ramyar AM Stanley SB Gabelli DW Denney Jr DJ Leahy 2003 Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab Nature 421 756 760
40. Y Durocher S Perret A Kamen 2002 High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells Nucleic Acids Res 30 E9
41. Gan SK, Hunt J, Beavil AJ, Marsh PJ, Harries HE (2008) The design and optimisation of a transient expression system for the rapid expression of human immunoglobulin E. Example cited in GB patent application 61/060,239
42. JM McDonnell R Calvert RL Beavil AJ Beavil AJ Henry BJ Sutton HJ Gould D Cowburn 2001 The structure of the IgE Cepsilon2 domain and its role in stabilizing the complex with its high-affinity receptor FcepsilonRIalpha Nat Struct Biol 8 437 441
43. AJ Henry JP Cook JM McDonnell GA Mackay J Shi BJ Sutton HJ Gould 1997 Participation of the N-terminal region of Cepsilon3 in the binding of human IgE to its high-affinity receptor FcepsilonRI Biochemistry 36 15568 15578
44. C Sundstrom K Nilsson 1976 Establishment and characterization of a human histiocytic lymphoma cell line (U-937) Int J Cancer 17 565 577
45. TH Corbett DP Griswold Jr BJ Roberts JC Peckham FM Schabel Jr 1975 Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure Cancer Res 35 2434 2439
46. DP Griswold TH Corbett 1975 A colon tumor model for anticancer agent evaluation Cancer 36 2441 2444
47. ML Penichet PM Challita SU Shin SL Sampogna JD Rosenblatt SL Morrison 1999 In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice Lab Anim Sci 49 179 188
48. TW Wiegand PB Williams SC Dreskin MH Jouvin JP Kinet D Tasset 1996 High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I J Immunol 157 221 230
49. M Bracher HJ Gould BJ Sutton D Dombrowicz SN Karagiannis 2007 Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis J Immunol Methods 323 160 171
50. M Bodinier C Brossard S Triballeau M Morisset C Guerin-Marchand F Pineau P de Coppet DA Moneret-Vautrin U Blank S Denery-Papini 2008 Evaluation of an in vitro mast cell degranulation test in the context of food allergy to wheat Int Arch Allergy Immunol 146 307 320
51. S Linko-Lopponen M Makinen 1985 A microtiter plate assay for n-acetyl-beta-d-glucosaminidase using a fluorogenic substrate Anal Biochem 148 50 53
52. JA Casal A Chabas JC Tutor 2003 Thermodynamic determination of beta-hexosaminidase isoenzymes in mononuclear and polymorphonuclear leukocyte populations Am J Med Genet A 116A 229 233
53. RB Gerstner P Carter HB Lowman 2002 Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody J Mol Biol 321 851 862
54. RG Posner D Geng S Haymore J Bogert I Pecht A Licht PB Savage 2007 Trivalent antigens for degranulation of mast cells Org Lett 9 3551 3554
55. AB Riemer E Jensen-Jarolim 2007 Mimotope vaccines: epitope mimics induce anti-cancer antibodies Immunol Lett 113 1 5
56. KH Bramswig R Knittelfelder S Gruber E Untersmayr AB Riemer K Szalai R Horvat R Kammerer W Zimmermann CC Zielinski 2007 Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice Clin Cancer Res 13 6501 6508
57. JV Ravetch JP Kinet 1991 Fc receptors Annu Rev Immunol 9 457 492